Separately, the Thai joint venture firm aims to directly manage some of its funds in Thailand.
Tag: Eastspring Investments
The FSA Spy market buzz – 21 June 2019
Eastspring’s Greenhouse; UBS’s faux-pas; Shanghai-London Connect; Bears and central banks; Gartner and Bitcoin; Carrie Lam gets of her horse; Li Ka Shing and much more.
Mutual Fund Top Trumps – Asia high yield
This week FSA presents a quick comparison of two Asia high yield bond products: the Eastspring Investments Asian High Yield Bond Fund and the UBS (Lux) Bond SICAV Asian High Yield (USD) Fund.
Eastspring to launch global growth fund in Singapore
The firm has also rolled out an Islamic equity fund in Malaysia.
Global firms ready onshore China funds
Eastspring, JP Morgan and Morgan Stanley face a six-month deadline to roll out their debut onshore products.
In case you missed it (19 October 2018)
JP Morgan AM names new APAC CEO; Eastspring completes TMB AM acquisition; UBP launches “positive impact” strategy; DWS launches Asia-focused fixed income fund in Hong Kong; Allianz GI’s ESG-integrated assets reach $132bn; SFC posts wanted list on its website; and more…
Taiwan unveils privileges for overseas managers
This year’s beneficiaries are Alliance Bernstein, Allianz Global Investors, Eastspring Investments, Schroders, Fidelity International, Franklin Templeton Investments and JP Morgan Asset Management.
The FSA Spy market buzz – 28 September 2018
Matthews hires; Algebris relocates; Eastspring poaches; Vanguard and ESG; Marijuana stocks; Discretionary mandates; Shanghai underground; Advertising and much more.
Eastspring steps up multi-asset game
Eastspring Investments is looking at ESG- and China-focused multi-asset products while adding people to the investment team, according to Colin Graham, Singapore-based chief investment officer for multi-asset solutions.
Shortage of A-share analysts dawns on UK firms
The inclusion of 230-odd China A-shares was a hugely symbolic moment for UK and European investors but the region’s fund industry has failed to get ahead of the curve, with most firms lacking dedicated teams of analysts or products to invest in.
